Novartis (NVS) Reports New Cosentyx® Data in Polymyalgia Rheumatica

Novartis AG (NYSE:NVS) is one of the best cheap stocks to buy for beginners. Novartis AG (NYSE:NVS) announced on June 3 new Cosentyx® data in polymyalgia rheumatica showing a statistically significant, clinically meaningful difference in sustained remission rates compared to placebo, and significant steroid sparing. Management reported that the Phase III REPLENISH data highlighted that the effect of Cosentyx treatment was sustained through week 52 in this investigational use, with the data published simultaneously in the New England Journal of Medicine and presented at the 2026 European Alliance of Associations for Rheumatology (EULAR) Congress.

Novartis AG (NYSE:NVS) further reported that the REPLENISH trial met all primary and secondary endpoints across both Cosentyx 300mg and 150mg treatment arms, including complete sustained remission and time until patients needed additional treatment through week 52. It also stated that no new safety signals were identified in PMR patients receiving Cosentyx. Prof Christian Dejaco, Director, Dept of Rheumatology, South Tyrol Health Trust, Bruneck, Italy, stated that they are “encouraged by the REPLENISH trial results which showed that Cosentyx, with its known safety profile, can reduce flares in the longer term while lowering patients’ steroid exposure.”

Headquartered in Basel, Switzerland, Novartis AG (NYSE:NVS) develops, markets, and manufactures a range of healthcare and pharmaceutical products, and is also involved in immuno-oncology research. Its operations span the Innovative Medicines, Sandoz, and Corporate segments.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.